Results 81 to 90 of about 2,348 (179)

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma [PDF]

, 2017
Background: Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and pharmacokinetics of sonidegib in children with relapsed/recurrent tumors followed by a phase II trial in pediatric and adult ...
Chisholm, J, Alba A Brandes, Riccardo Riccardi, Mark W Kieran, Eric Bouffet, Kenneth J Cohen, Mason, W, Tai, F, Simon Bailey, Bouffet, E, Eunju Hurh, Hurh, E, Darren Hargrave, Hargrave, D, Stacey Kalambakas, Cohen, KJ, MacDonald, TJ, Isabelle Aerts, Birgit Geoerger, Michela Casanova, Tobey J MacDonald, Francoise Mechinaud, Bailey, S, Casanova, M, Brandes, AA, Leary, S, Aerts, I, Feng Tai, Kieran, MW, Mechinaud, F, Deshpande, P, Geoerger, B, Warren Mason, Riccardi, R, Kalambakas, S, Julia Chisholm, Priya Deshpande, Sarah Leary   +37 more
core   +1 more source

Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.

PLoS ONE
Basal cell carcinoma (BCC) is highly curable by surgical excision or radiation. In rare cases, BCC can be locally destructive or difficult to surgically remove. Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50-60% response rate.
Shivani Patel, Heather Armbruster, Gretchen Pardo, Brianna Archambeau, Na Hyun Kim, Joanne Jeter, Richard Wu, Kari Kendra, Carlo M Contreras, Natalie Spaccarelli, Brittany Dulmage, Llana Pootrakul, David R Carr, Claire Verschraegen   +13 more
doaj   +1 more source

Real-Life Experience with Sonidegib for Locally Advanced Basosquamous Carcinoma: A Case Series

Case Reports in Dermatology
Introduction: Basosquamous carcinoma is an uncommon subtype of basal cell carcinoma (BCC), characterized by aggressive local growth and metastatic potential, that mainly develops on the nose, perinasal area, and ears, representing 1.2–2.7% of all head ...
Enrico Bocchino, Simone Cappilli, Gerardo Palmisano, Andrea Paradisi, Alfredo Piccerillo, Alessandro Di Stefani, Ketty Peris   +6 more
doaj   +1 more source

Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors

, 2017
Sonidegib is a selective inhibitor of Smoothened receptor, which is a key regulator of the Hedgehog signaling pathway. The purpose of this study was to determine the maximum tolerated dose based on dose-limiting toxicity (DLT) and the recommended dose ...
Minami, Hironobu;Ando, Yuichi;Ma, Brigette Buig Yue;Lee, Jih-Hsiang;Momota, Hiroyuki;Fujiwara, Yutaka;Li, Leung;Fukino, Koichi;Ito, Koji;Tajima, Takeshi;Mori, Asuka;Lin, Chia-Chi, 林家齊;李日翔   +1 more
core   +1 more source

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

, 2015
BACKGROUND Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around 95% of tumours.
Dirix, Luc, Guminski, Alexander, Yi, Tingting, Stratigos, Alexander J, Mone, Manisha, Lear, John T, Chang, Anne Lynn S., Migden, Michael R, Cornélis, Frank, Lear, John T., Chang, Anne Lynn S, Lewis, Karl D, Loquai, Carmen, Plummer, Ruth, Migden, Michael R., Stratigos, Alexander J., Gutzmer, Ralf, Sellami, Dalila, Gogov, Sven, Combemale, Patrick, Herd, Robert M., Kaatz, Martin, Dummer, Reinhard, Trefzer, Uwe, Schulze, Hans-Joachim, Pallaud, Celine, Herd, Robert M, Kudchadkar, Ragini, Lewis, Karl D.   +28 more
core   +1 more source

Fabrication and In Vivo Evaluation of In Situ pH-Sensitive Hydrogel of Sonidegib–Invasomes via Intratumoral Delivery for Basal Cell Skin Cancer Management

Pharmaceuticals
Background/Objectives: Basal cell skin cancer (BCSC) develops when skin cells proliferate uncontrollably. Sonidegib (SDB) is a therapeutic option for the treatment of BCSC by inhibiting hedgehog signaling.
Maha M. Ghalwash, Amr Gamal Fouad, Nada H. Mohammed, Marwa M. Nagib, Sherif Faysal Abdelfattah Khalil, Amany Belal, Samar F. Miski, Nisreen Khalid Aref Albezrah, Amani Elsayed, Ahmed H. E. Hassan, Eun Joo Roh, Shaimaa El-Housiny   +11 more
doaj   +1 more source

Sonidegib [PDF]

, 2020
openaire   +1 more source

Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial

Clinical, Cosmetic and Investigational Dermatology, 2020
John T Lear,1 Axel Hauschild,2 Eggert Stockfleth,3 Nicholas Squittieri,4 Nicole Basset-Seguin,5 Reinhard Dummer6 1Manchester Royal Infirmary, Manchester, UK; 2Klinik Für Dermatologie, Venerologie Und Allergologie Universitätsklinikum Schleswig ...
Lear JT, Hauschild A, Stockfleth E, Squittieri N, Basset-Seguin N, Dummer R   +5 more
doaj  

Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options

Biomedicines
Non-melanoma skin cancers (NMSC) form the majority of skin cancers, with basal cell carcinoma (BCC) being the most common and cutaneous squamous cell carcinoma (cSCC) being second.
Zoe Gabrielle Attal, Walid Shalata, Arina Soklakova, Lena Tourkey, Sondos Shalata, Omar Abu Saleh, Fahed Abu Salamah, Ibrahim Alatawneh, Alexander Yakobson   +8 more
doaj   +1 more source

Sonidegib treatment in patients with locally advanced basal cell carcinoma [PDF]

Dermatologic Therapy, 2022
Villani A., Fabbrocini G., Scalvenzi M.
openaire   +3 more sources